Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 2 Small Cell Lung Carcinoma 1 Rectal Neoplasms 1 Radiation-induced Injuries in Patients With Rectal Cancer 1 Radiation Injuries 1 Precancerous Conditions 1 Neoplasms, Second Primary 1 Neoplasms 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Fibrosis 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Adenomatous Polyps 1

Interventions

Cyclophosphamide 149 Docetaxel 139 Paclitaxel 127 Trastuzumab 120 Tamoxifen 110 Capecitabine 104 Letrozole 92 Epirubicin 79 Doxorubicin 70 Anastrozole 70 exemestane 67 Fulvestrant 65 Fluorouracil 61 Radiotherapy 60 pertuzumab 40 Gemcitabine 39 Carboplatin 38 Vinorelbine 34 Goserelin 34 Bevacizumab 29 Zoledronic Acid 28 Methotrexate 28 Chemotherapy, Adjuvant 28 eribulin 27 Lapatinib 25 ribociclib 24 palbociclib 24 Drug Therapy 22 130-nm albumin-bound paclitaxel 20 pegfilgrastim 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Breast Neoplasms × alpha-Tocopherol × Clear all

NCT02898376 2018-08-08

FIBROTHERME

Institut de Cancérologie de Lorraine

Phase 3 Unknown

Breast Neoplasms, Fibrosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡